Polyamine reduced diet and low dose metronomic cyclophosphamide in hormone refractory prostate cancer (HRPC) patients

被引：0
|
作者：
Cipolla, B. G. [1 ,2 ]
Havouis, R. [1 ]
Moulinoux, J. P. [1 ]
机构：
[1] Univ Rennes 1, CNRS, URA 1529, F-35014 Rennes, France
[2] CHP St Gregoire, Rennes, France
来源：
AMINO ACIDS | 2009年 / 37卷 / 01期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：51 / 52
页数：2
相关论文
共 50 条
  • [41] Out-patient low-dose oral chemotherapy in hormone refractory prostate carcinoma (HRPC) patients unfit for hospital admittance
    Serretta, Vincenzo
    Altieri, Vincenzo
    Morgia, Giuseppe
    Siragusa, Alfredo
    De Grande, Gaetano
    Orestano, Luigi
    Napoli, Matteo
    Falsaperla, Mario
    Melloni, Darvinio
    Allegro, Rosalinda
    JOURNAL OF UROLOGY, 2008, 179 (04): : 183 - 183
  • [42] RETROSPECTIVE EVALUATION OF THERAPY WITH KETOCONAZOLE IN HORMONE-REFRACTORY PROSTATE CANCER (HRPC)
    Bonetta, Alberto
    Derelli, Roberto
    ANTICANCER RESEARCH, 2011, 31 (05) : 1942 - 1943
  • [43] Weekly docetaxel for advanced hormone-refractory prostate cancer-HRPC
    Pepe, A.
    Usset, A.
    Calabria, C.
    Savio, G.
    Palmisano, V
    Leonardi, V
    Laudani, A.
    Arcuri, C.
    Giresi, A.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2006, 17 : XI82 - XI82
  • [44] Vinorelbine (VNB) and estramustine (EMP) in hormone-refractory prostate cancer (HRPC).
    Ferraù, F
    Morgia, G
    Priolo, D
    Vitale, F
    Parisi, A
    Mattina, M
    Calì, S
    ANNALS OF ONCOLOGY, 2000, 11 : 77 - 77
  • [45] LOW-DOSE METRONOMIC CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE AND METHOTREXATE IN METASTATIC BREAST CANCER PATIENTS
    Krajnak, S.
    Battista, M.
    Elger, T.
    Stewen, K.
    Heimes, A. S.
    Hasenburg, A.
    Schmidt, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 636 - 636
  • [46] LOW-DOSE METRONOMIC CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE AND METHOTREXATE IN METASTATIC BREAST CANCER PATIENTS
    Krajnak, S.
    Battista, M.
    Elger, T.
    Stewen, K.
    Heimes, A. S.
    Hasenburg, A.
    Schmidt, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 116 - 116
  • [47] Advantages of Second Line Estramustine for Overall Survival of Hormone-Refractory Prostate Cancer (HRPC) Patients
    Naiki, Taku
    Okamura, Takehiko
    Kawai, Noriyasu
    Sakagami, Hiroshi
    Yamada, Yasuyuki
    Fujita, Keiji
    Akita, Hidetoshi
    Hashimoto, Yoshihiro
    Tozawa, Keiichi
    Kohri, Kenjiro
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2009, 10 (01) : 71 - 74
  • [48] Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC)
    Papatsoris, AG
    Karamouzis, MV
    Papavassiliou, AG
    CURRENT MEDICINAL CHEMISTRY, 2005, 12 (03) : 277 - 296
  • [49] Weekly docetaxel for advanced hormone-refractory prostate cancer-hrpc
    Pepe, A.
    Usset, A.
    Calabria, C.
    Savio, G.
    Palmisano, V
    Leonardi, V
    Laudani, A.
    Arcuri, C.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : 187 - 187
  • [50] Anti-inflammatory and angiostatic therapy in hormone refractory prostate cancer (HRPC)
    Albrecht, M.
    Vogelhuber, M.
    Stenzl, A.
    Feyerabend, S.
    Walter, B.
    Schulze, M.
    Oberneder, R.
    Rohrmann, K.
    Schmidt, K.
    Reichle, A. R.
    EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 233 - 233
12345